Linked Life Data

3279486

Source:http://linkedlifedata.com/resource/pubmed/id/3279486

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1988-4-14
pubmed:abstractText
Despite similarities in their chemical structures, the new fluoroquinolones differ greatly in the extent to which renal clearance contributes to their elimination. On the opposite ends of this spectrum are ofloxacin, which is almost entirely eliminated by the kidney as unmodified drug, and pefloxacin, which undergoes extensive biotransformation. Dosage adjustments in patients with renal insufficiency therefore are recommended for ofloxacin, but, on the basis of currently available data, adjustments do not appear to be required for pefloxacin. Both renal clearance of unmodified drug and metabolic transformation contribute substantially to the elimination of norfloxacin and ciprofloxacin. Because of the great antimicrobial potency of the new fluoroquinolones, it should be possible to employ them in the treatment of urinary tract infections caused by highly susceptible bacteria even in patients with marked impairment of renal function.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0162-0886
pubmed:author
pubmed:issnType
Print
pubmed:volume
10 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S102-5
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:articleTitle
New quinolones: pharmacology, pharmacokinetics, and dosing in patients with renal insufficiency.
pubmed:affiliation
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
pubmed:publicationType
Journal Article, Review